共 76 条
[1]
Hortobagyi GN(1998)Treatment of breast cancer N Engl J Med 339 974-984
[2]
Hamilton A(2005)Chemotherapy: what progress in the last 5 years? J Clin Oncol 23 1760-1775
[3]
Hortobagyi G(2002)Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European organization for research and treatment of cancer 10961 multicenter phase III trial J Clin Oncol 20 3114-3121
[4]
Biganzoli L(2001)Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial J Clin Oncol 19 1707-1715
[5]
Cufer T(2003)Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 588-592
[6]
Bruning P(2001)UKCCCR trial of epirubicin and cyclophosphamide (EC) vs. epirubicin and Taxol® (ET) in the first line treatment of women with metastatic breast cancer (MBC) Proc Am Soc Clin Oncol 20 22a-45
[7]
Jassem J(1995)Doxorubicin-induced cardiotoxicity N Engl J Med 333 1360-2008
[8]
Pienkowski T(2003)Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial Cancer 97 40-992
[9]
Pluzanska A(2001)Side effects of adjuvant treatment of breast cancer N Engl J Med 344 1997-1833
[10]
Sledge GW(1994)Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res 54 987-449